News Search Results
Nov 26, 2025, 17:09 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Nov 26, 2025, 01:48 ET Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
ZYMFENTRA.NEUROLOGIC REACTIONSAgents that inhibit TNF have been associated with central nervous system (CNS) manifestation of systemic vasculitis, seizure and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis and peripheral demyelinating disorders,
More news about: Celltrion
Nov 25, 2025, 05:01 ET Generic Drugs Market Size to Worth USD 898 Billion by 2035, at a CAGR of 5.75% | Research by Vantage Market Research
complex generics requiring advanced delivery systems.By Therapeutic ApplicationCentral Nervous System (CNS): CNS generics maintain strong demand due to high prevalence of epilepsy, depression, anxiety, and neurodegenerative conditions. Patent expires in psychiatric
More news about: Vantage Market Research
Nov 24, 2025, 10:01 ET Regenerative Medicine Market to Skyrocket to USD 403.86 Billion by 2032 Driven by Cell & Gene Therapy Breakthroughs, Stem Cell Advancements, and Multi-Indication Expansion
TherapyStem cell therapy accounted for 17% (USD 8.2 billion), driven by allogeneic and autologous products for musculoskeletal, dermatology, CNS, and cardiovascular applications. MSC-based therapies continue to dominate due to their strong safety profile and multi-organ repair potential.By
More news about: DataM Intelligence 4 Market Research LLP
Nov 24, 2025, 10:00 ET GEMMABio Announces Clinical Trial Authorization for New SMA1 Gene Therapy
proprietary central nervous system (CNS) platform technology, developed by Dr. Wilson's research team and licensed from the University of Pennsylvania, showed a reassuring preclinical safety profile and durable expression in NHP studies. Notably, in research animals, the direct CNS delivery via ICM injection
More news about: GEMMA Biotherapeutics
Nov 24, 2025, 05:19 ET Drs. Elliott Brea, Esther Redin, and Gavitt Woodard Announced as Recipients of LUNGevity's Career Development Awards
treatment directly into the CNS tumor site, to reduce contact with healthy tissue expressing TROP-2. The second method is to genetically modify the CAR-T cells to limit their ability to enter healthy epithelial tissue. If successful, this research will revolutionize the way we treat CNS in patients with EGFR-positive
More news about: LUNGevity Foundation
Nov 21, 2025, 13:30 ET Researchers Highlight Genetic Factors in Pediatric Brain and Spinal Cord Tumors
nervous system (CNS) are the leading cause of cancer-related deaths in children, with more than 47,000 children and young adults diagnosed each year. While up to one in four children with cancer carry rare genetic variants that increase cancer risk, the specific genetic drivers of pediatric CNS tumors remain
More news about: Children's Hospital of Philadelphia
Nov 21, 2025, 08:04 ET SK Life Science, Inc. to Present 10 Posters with New Cenobamate Data, Including a Late-Breaker, at the 2025 American Epilepsy Society (AES) Annual Meeting
SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., will present new data on cenobamate, an anti-seizure medication, at the 2025 American
More news about: SK Life Science, Inc.
Nov 21, 2025, 03:01 ET HRV Pharma and MetroChem Forge Strategic CDMO Alliance to Fast-Track High-Value NCE-1 API Development
marketsGlobal regulatory DMF filings (US, EU, LATAM, MENA & APAC) with shared technical dossiersA long-term, pipeline-led framework covering novel CNS, metabolic and specialty therapeutic APIsA unified quality, compliance and audit readiness program designed for USFDA, EMA, PMDA, ANVISA and
More news about: HRV Pharma
Nov 20, 2025, 15:00 ET Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference
a clinical stage drug discovery and development company, dedicated to engineering and developing best-in-class therapeutics for treating metabolic, CNS, inflammatory, fibrotic, and multiple other disease indications including where ROCK2 plays a pivotal role in pathology. Graviton's first drug candidate,
More news about: Graviton Bioscience
Nov 20, 2025, 08:30 ET Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight important differences between treatments Review presents distinctive
More news about: Neurocrine Biosciences, Inc.
Nov 20, 2025, 07:00 ET SciNeuro Pharmaceuticals to Accelerate Novel LRRK2 Therapeutic (SNP614) Development with an Award from The Michael J. Fox Foundation
immune response. The company aims to develop disease-modifying treatment options for Alzheimer's disease, Parkinson's disease, and other devastating CNS diseases. For more information, please visit
More news about: SciNeuro Pharmaceuticals
Nov 19, 2025, 16:19 ET Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Nov 19, 2025, 08:48 ET Ventoux Biosciences Launches Research Program Targeting Spinal Cord Injury with VEN-201
with over 25 years in the industry, I've seen how fibrosis is often overlooked in CNS repair. VEN-201's localized anti-fibrotic profile offers a compelling rationale for CNS applications, and Dr. Sofroniew's expertise in CNS injury mechanisms makes this research particularly valuable."
More news about: Ventoux Biosciences
Nov 18, 2025, 12:01 ET ISMP Announces 28th Annual Cheers Award Recipients
a 2025 ISMP Medication Safety Officers Society briefing. MiKaela Olsen, DNP, APRN-CNS, AOCNS, FAAN, and AnnMarie Walton, PhD, MPH, RN, OCN, CHES, FAAN Baltimore,
More news about: Institute for Safe Medication Practices
Nov 17, 2025, 09:07 ET Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
About (Z)-Endoxifen(Z)-Endoxifen is Atossa's investigational ER-modulating small molecule. In oncology and CNS studies to date, (Z)-endoxifen has shown a favorable safety profile and pharmacology distinct from tamoxifen, including ER-targeted effects and PKC inhibition.
More news about: Atossa Therapeutics Inc
Nov 17, 2025, 08:30 ET Cipla USA Strengthens Lung Leadership with Community Wellness Initiatives
Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms
More news about: Cipla USA Inc.
Nov 17, 2025, 08:04 ET SK Life Science, Inc. Announces Publication of C035 Study Analyses in Epilepsia and Seizure
SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., today announced the recent publication of three peer-reviewed articles evaluating the
More news about: SK Life Science, Inc.
Nov 17, 2025, 06:30 ET Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Nov 16, 2025, 21:29 ET Akeso's Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China
options for Alzheimer's patients. CNS disorders have long posed significant therapeutic challenges on a global scale. Akeso, with its deep expertise in bispecific antibody development, is at the forefront of creating novel therapies to address critical unmet clinical needs in CNS diseases.
More news about: Akeso, Inc.
Nov 15, 2025, 11:00 ET BrainXell Showcases Pioneering iPSC Research and Promising In Vivo Data for BXT-110 for Parkinson's Disease at the 2025 Society for Neuroscience Annual Meeting
system of endothelial cells, astrocytes, and pericytes accurately replicates barrier integrity and permeability, providing a quantitative platform for CNS drug transport and safety studies. Poster presentation: Nov. 15th at 1:00 p.m. at location #369.09. Another study details an accelerated
More news about: BrainXell, Inc
Nov 14, 2025, 16:05 ET Cohen & Steers Announces Changes to Realty Indexes
NEW YORK, Nov. 14, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today pending changes to its Global Realty Majors Portfolio Index (GRM) and International Realty Majors Portfolio Index (IRP), effective as
More news about: Cohen & Steers, Inc.
Nov 14, 2025, 16:01 ET Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib
for central nervous system (CNS) penetrance to improve treatment options for patients with brain metastases, and to avoid inhibition of the structurally related tropomyosin receptor kinase (TRK) family. Together, these characteristics have the potential to avoid TRK-related CNS adverse events seen with
More news about: Nuvalent, Inc.
Nov 14, 2025, 09:26 ET Curis to Present at Upcoming 30th Annual SNO Meeting
orally available, small molecule IRAK4 inhibitor, today announced that Curis will report emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations and preclinical data on emavusertib in an oral presentation at the 30th Annual Meeting of the
More news about: Curis, Inc.
Nov 13, 2025, 08:33 ET CNS Summit 2025 Honors Robert Langer with Leadership Award for Transformative Impact in Life Sciences Innovation
Nov. 13, 2025 /PRNewswire/ -- The Leadership Council of CNS Summit (Collaborating for Novel Solutions) is proud to announce that Robert S. Langer, Institute Professor at MIT, has been selected as recipient of the 2025 CNS Summit Leadership Award in recognition of his enduring contributions
More news about: CNS Summit